An announcement from Hearts and Minds Investments Ltd ( (AU:HM1) ) is now available.
Hearts and Minds Investments Limited (HM1) has announced an update regarding its investment in Opthea Limited (OPT), a biopharmaceutical company focused on developing therapies for eye diseases. OPT reported negative results from a Phase 3 clinical trial of its lead drug candidate, leading to a suspension of its securities on the ASX and Nasdaq. Consequently, HM1 has revalued its holding in OPT, impacting its net asset value by approximately 1.6%. This adjustment reflects the potential for future positive outcomes from upcoming trials.
More about Hearts and Minds Investments Ltd
Hearts and Minds Investments Limited (HM1) is an investment company that focuses on managing a diversified portfolio. The company is involved in the financial services industry, providing investment opportunities and portfolio management services to its stakeholders.
YTD Price Performance: -1.99%
Average Trading Volume: 201,586
Technical Sentiment Signal: Sell
See more data about HM1 stock on TipRanks’ Stock Analysis page.